We are live on ! Find out more
PMVP icon

PMV Pharmaceuticals
PMVP

Fund managers haven’t disclosed any holdings of PMVP yet.

PMVP Hedge Fund Activity: Q1 2026 in Review

69 of the 8,141 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q1 2026, worth a combined $45.8M — down 2% from $46.8M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new PMVP positions and 8 closed out — a net gain of 7 holders — while 16 added to existing stakes and 20 trimmed.

The largest buyer was Eversept Partners, opening a new position worth an estimated $2.99M. The largest seller was OrbiMed, exiting entirely with an estimated $6.22M sold.

  • 69 institutional investors held PMV Pharmaceuticals (PMVP) as of Q1 2026, up from 63 in Q4 2025.
  • Funds reported $45.8M of PMV Pharmaceuticals stock for Q1 2026, down 2% quarter-over-quarter.
  • 15 funds opened new PMV Pharmaceuticals positions in Q1 2026 and 8 closed out, a net change of +7 holders.
  • The largest PMV Pharmaceuticals buyer in Q1 2026 was Eversept Partners, an estimated $2.99M added.
  • The largest PMV Pharmaceuticals seller in Q1 2026 was OrbiMed, an estimated $6.22M sold.

Based on aggregated 13F filings for Q1 2026.